The present invention provides an erythropoietin-derived peptide whose amino acid sequence is represented by SEQ ID NO: 1. The present invention further provides a method for producing the erythropoietin-derived peptide. Furthermore, there is provided an application of the erythropoietin-derived peptide in the manufacture of a medicament for treating nerve cell damage. Further, the present invention provides an application of the erythropoietin-derived peptide in the manufacture of a medicament for treating hypoxic encephalopathy. Furthermore, there is provided the application of the erythropoietin-derived peptide in the manufacture of a medicament for treating epilepsy. The novel drug of the novel EPO-derived peptide of the present invention has a small molecular weight, can penetrate the blood-brain barrier, is a low-molecular polypeptide derived from a functional protein in the human body, and is compared with other developed synthetic drugs. The side effects on the human body are extremely small, and the possibility of clinical application can be expected. The present invention, when applied clinically, becomes a novel neuroprotective medicine for preventing and treating central nervous system diseases, and can provide a new treatment method for patients with nerve injury.本発明は、そのアミノ酸配列が配列番号１で示されるエリスロポエチン由来ペプチドを提供する。本発明は、さらに前記エリスロポエチン由来ペプチドの製造方法を提供する。さらに、神経細胞損傷の治療のための医薬品の製造における前記エリスロポエチン由来ペプチドの適用を提供する。さらに、低酸素脳症の治療のための医薬品の製造における前記エリスロポエチン由来ペプチドの適用を提供する。さらに、てんかんの治療のための医薬品の製造における前記エリスロポエチン由来ペプチドの適用を提供する。本発明の新規なＥＰＯ由来ペプチドの新薬品は、分子量が小さく、血液脳関門を透過でき、人体内の機能性タンパク質由来の低分子ポリペプチドであり、開発された他の合成医薬品と比較して、人体への副作用が極めて小さく、臨床適用の可能性が期待できる。該発明は臨床適用される場合、中枢神経系疾患を予防及び治療するための新規な神経保護医薬品になり、神経損傷の患者に新たな治療法を提供できる。
